Kazuhiko Kawakami

AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Katsuyoshi Matsuoka, Mamoru Watanabe, Toshihide Ohmori et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 78 citations

Inflammation, Anti-inflammatory, Gastrointestinal Pharmacology +9

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Marc Ferrante, Geert D’Haens, Vipul Jairath et al. · The Lancet · 2024 · 76 citations

Moderately-to-severely Active Crohn, Immunology, Gastroenterology +5

Usefulness of Machine Learning-Based Gut Microbiome Analysis for Identifying Patients with Irritable Bowels Syndrome

Hirokazu Fukui, Akifumi Nishida, Satoshi Matsuda et al. · Journal of Clinical Medicine · 2020 · 69 citations · Full text

C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease

Toshifumi Hibi∥, Atsushi Sakuraba, Mamoru Watanabe et al. · Journal of Gastroenterology · 2013 · 58 citations

Inflammation, Chronic Inflammatory Diseases, Serum Infliximab Level +12

Retrieval of Serum Infliximab Level by Shortening the Maintenance Infusion Interval Is Correlated with Clinical Efficacy in Crohnʼs Disease

Toshifumi Hibi∥, Atsushi Sakuraba, Mamoru Watanabe et al. · Inflammatory Bowel Diseases · 2011 · 53 citations · Full text